Deals > All

East Germany North Germany South Germany West Germany Austria Germany Switzerland [ # 12 & 35 ]

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4182 | Ordered by Date (descending)
1 2 3 ... 40 41 42

Deal: Collaboration or Financing	Date
Windward Bio–Omega Funds: investment, 202501 financing round Series A totalling $200m incl co-investor Omega Funds	2025-01-10
Windward Bio–OrbiMed: investment, 202501 financing round Series A totalling $200m incl co-lead investor OrbiMed	2025-01-10
Windward Bio–Qiming: investment, 202501 financing round Series A totalling $200m incl co-investor Qiming Venture Partners	2025-01-10
Windward Bio–Quan Capital: investment, 202501 financing round Series A totalling $200m incl co-investor Quan Capital	2025-01-10
Windward Bio–RTW Investments: investment, 202501 financing round Series A totalling $200m incl co-investor RTW Investments	2025-01-10
Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities	2025-01-10
Windward Bio–SR One: investment, 202501 financing round Series A totalling $200m incl co-investor SR One	2025-01-10
Boehringer–Lonza: ADC technology, 202501– license to Synaffix ADC technology €na upfront + $1.3b milestones plus royalties	2025-01-09
Graph Therapeutics–SEVERAL: investment, 202501 pre-seed financing round $3.1m led by Squareone + Merantix Capital	2025-01-09
Numab–Cormorant Asset Management: investment, 202501 financing round Series C extension totalling CHF50m incl existing + co-lead investor Cormorant AM	2025-01-09
Numab–SEVERAL: investment, 202501 financing round Series C extension CHF50m bringing total Series C to CHF180m	2025-01-09
Alesta Therapeutics–Novartis: investment, 202501 financing round Series A totalling €65m incl co-investor Novartis Venture Fund	2025-01-08
Alesta Therapeutics–SEVERAL: investment, 202501 financing round Series A €65m co-led by Frazier Life Sciences + Droia Ventures	2025-01-08
Alesta Therapeutics–Vetter: investment, 202501 financing round Series A totalling €65m incl co-investor RV Invest	2025-01-08
Orbis Medicines–Cormorant Asset Management: investment, 202501 financing round Series totalling €90m incl new + co-investor Cormorant	2025-01-06
Orbis Medicines–Denmark (govt): investment, 202501 financing round Series totalling €90m incl new + co-investor EIFO	2025-01-06
Orbis Medicines–Forbion: investment, 202501 financing round Series totalling €90m incl existing + co-investor Forbion	2025-01-06
Orbis Medicines–Lilly: investment, 202501 financing round Series totalling €90m incl new + co-investor Eli Lilly	2025-01-06
Orbis Medicines–New Enterprise Associates: investment, 202501 financing round Series totalling €90m incl new + lead investor NEA	2025-01-06
Orbis Medicines–Novo Group: investment, 202501 financing round Series totalling €90m incl existing + co-investor Novo Holdings	2025-01-06
Orbis Medicines–SEVERAL: investment, 202501 financing round Series €90m led by NEA	2025-01-06
Roche–Innovent Biologics: antibody-drug conjugate, 202501– collab + excl ww license to IBI3009 with $80m upfront + $1b milestones plus royalties	2025-01-02
Gemma Biotherapeutics–Earlybird: investment, 202412 seed financing round totalling $34m incl co-lead investor Earlybird Venture Capital	2024-12-23
Gemma Biotherapeutics–SEVERAL: investment, 202412 seed financing round $34m led by Doube Point Ventures + Bioluminescence Ventures + Earlybird VC	2024-12-23
Univ Zurich–Bruker: NMR spectrometer, 202412 supply 1.2 GHz Ascend NMR spectrometer to Swiss High-field NMR Facility at UZH	2024-12-20
Novartis–BioAge Labs: drug target discovery, 202412– collab multi-year $20m upfront + $530m milestones identify targets for age-related diseases	2024-12-18
HUB Organoids–Merck (DE): investment, 202412– acquisition €na of HUB Organoids Holding BV by Merck SIGNED	2024-12-17
Formo Bio–EU (govt): credit, 202412– venture debt loan €35m from EIB	2024-12-16
Mainz Biomed–SEVERAL: investment, 202412 follow-on offering $8m with 1.37m units (1 share + 1 Class A + 1 Class B warrant) at $5.85/unit	2024-12-16
RhyGaze–Alphabet: investment, 202412 financing round Series A totalling $86m incl new + lead investor GV	2024-12-13
RhyGaze–ARCH Venture: investment, 202412 financing round Series A totalling $86m incl new + co-investor ARCH Venture Partners	2024-12-13
RhyGaze–BioGeneration Ventures: investment, 202412 financing round Series A totalling $86m incl existing + co-investor BGV	2024-12-13
RhyGaze–F-Prime: investment, 202412 financing round Series A totalling $86m incl new + co-investor F-Prime Capital	2024-12-13
RhyGaze–Novartis: investment, 202412 financing round Series A totalling $86m incl existing + co-investor NVF	2024-12-13
RhyGaze–SEVERAL: investment, 202412 financing round Series A $86m led by GV	2024-12-13
Andera Partners–New York Life: investment, 202412– acquisition €na of 40% minority share in Andera by New York Life Investments	2024-12-12
Fresenius–Ori Biotech: CGT manufacturing technology, 202412– collab integration IRO platform with up + downstream processing tech of Fresenius Kabi	2024-12-10
Citryll–SEVERAL: investment, 202412 financing round Series B €85m co-led by JnJ JJDC + Forbion + Novartis Venture Fund	2024-12-09
Ariceum Therapeutics–Eckert & Ziegler: radionuclides, 202412– supply agreem ww for Ac-225 + Lu-177 to Ariceum	2024-12-05
Bruker–Ion Opticks: liquid chromatography, 202412– supply costum chromatography column for MS-based proteomic services to Biognosys	2024-12-05
Antag Therapeutics–Pictet: investment, 202412 financing round Series A totalling €80m incl co-investor Pictet	2024-12-04
Antag Therapeutics–SEVERAL: investment, 202412 financing round Series A €80m led by Versant Ventures	2024-12-04
Antag Therapeutics–Versant Ventures: investment, 202412 financing round Series A totalling €80m incl lead investor Versant Ventures	2024-12-04
HexagonFab–Merck (DE): investment, 202412 financing round Series A totalling £6.6m of Abselion incl lead investor M Ventures	2024-12-04
HexagonFab–SEVERAL: investment, 202412 financing round Series A £6.6m of Abselion led by M Ventures	2024-12-04
ViveBiotech–Ampersand: investment, 202412 growth equity investment from Ampersand Capital Partners	2024-12-04
Eppendorf–DataHow: laboratory software, 202412– collab strategic integration of DataHowLab s/w with BioNSight cloud	2024-12-02
Carl Roth–Bio Inx: bioinks, 202411– distribution ww of entire portfolio of bioinks of Bio Inx by Carl Roth	2024-11-27
Cradle Bio–Index Ventures: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Index Ventures	2024-11-26
Cradle Bio–Institutional Venture Partners: investment, 202411 financing round Series B totalling $73m incl new + lead investor IVP	2024-11-26
Cradle Bio–Kindred Capital: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Kindred Capital	2024-11-26
Cradle Bio–SEVERAL: investment, 202411 financing round Series B $73m led by IVP	2024-11-26
Eisbach Bio–Texas (govt): grant, 202411 CPRIT grant $4.75m to support Ph1/2 study of EIS-12656 at MD Anderson	2024-11-26
Grifols–Cradle Bio: protein engineering, 202411 supply existent Grifols is user of AI-based protein engineering platform	2024-11-26
JnJ–Cradle Bio: protein engineering, 202411 supply existent JnJ Innovative Medicine is user of AI-based protein engineering platform	2024-11-26
Kyan Health–Amplo: investment, <202411 seed financing round totalling $4m incl lead investor Amplo VC	2024-11-26
Kyan Health–Founderful: investment, 202411 financing round Series A totalling $12.7m incl co-investor Founderful	2024-11-26
Kyan Health–GreyMatter Capital: investment, 202411 financing round Series A totalling $12.7m incl co-investor GreyMatter Capital	2024-11-26
Kyan Health–Joyance Partners: investment, 202411 financing round Series A totalling $12.7m incl co-investor Joyance Partners	2024-11-26
Kyan Health–OTHER: investment, 202411 financing round Series A totalling $12.7m incl several angel investors	2024-11-26
Kyan Health–Schwabe: investment, 202411 financing round Series A totalling $12.7m incl co-investor NaturalX Health Ventures	2024-11-26
Kyan Health–SEVERAL: investment, 202411 financing round Series A $12.7m led by Swisscom Ventures	2024-11-26
Kyan Health–SEVERAL: investment, <202411 seed financing round $4m led by Amplo VC	2024-11-26
Kyan Health–Swisscom: investment, 202411 financing round Series A totalling $12.7m incl lead investor Swisscom Ventures	2024-11-26
Novo Group–Cradle Bio: protein engineering, 202411 supply existent Novo Nordisk is user of AI-based protein engineering platform	2024-11-26
Novonesis–Cradle Bio: protein engineering, 202411 supply existent Novonesis is user of AI-based protein engineering platform	2024-11-26
Poseida Therapeutics–Roche: investment, 202411– acquisition $1b in cash + up to $500k in CVRs by Roche	2024-11-26
Baccinex–Adragos Pharma: investment, 202411 acquisition €na of Baccinex by Adragos Pharma	2024-11-25
Bico–RAG: investment, 202411 acquisition €26m of Nanoscribe from Bico Group by LAB14 GmbH	2024-11-21
Kate Therapeutics–Novartis: investment, 202411 acquisition up to $1.1b incl upfront cash payment + milestones by Novartis	2024-11-21
Pep2Tango Therapeutics–Versant Venures: investment, 202411 investment round €na with Versant Ventures	2024-11-21
Evotec–Halozyme: investment, 202411 acquisition €2b unsolicited + non-binding cash offer at €11/share refused + withdrawn NOT REALISED	2024-11-14
Andera Partners–MC Services: public relations, 202411 service existent by MC Services	2024-11-13
Biotheus–BioNTech: investment, 202411– acquisition 100% for $800m upfront mostly in cash + few ADSs plus $150m milestones	2024-11-13
Centogene–Charme Capital Partners: investment, 202411–202503 acquisition €8.7m of sole operating subsidiary Centogene GmbH by Charme Capital	2024-11-13
Invios–MC Services: public relations, 202410 service existent by MC Services	2024-11-13
Alentis Therapeutics–Avego Bioscience Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Avego BC	2024-11-12
Alentis Therapeutics–Bellevue: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor BB Pureos	2024-11-12
Alentis Therapeutics–Catalio Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Catalio Capital	2024-11-12
Alentis Therapeutics–France (govt): investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor Bpifrance InnoBio 2 Fund	2024-11-12
Alentis Therapeutics–Frazier: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Frazier Life Sciences	2024-11-12
Alentis Therapeutics–Jeito Capital: investment, 202411 financing round Series D totalling $181.4m incl existing + co-lead investor Jeito Capital	2024-11-12
Alentis Therapeutics–Longitude Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Longitude Capital	2024-11-12
Alentis Therapeutics–Morningside: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor Morningside VI	2024-11-12
Alentis Therapeutics–Novo Group: investment, 202411 financing round Series D totalling $181.4m incl existing + co-lead investor Novo Holdings	2024-11-12
Alentis Therapeutics–OrbiMed: investment, 202411 financing round Series D totalling $181.4m incl lead investor OrbiMed	2024-11-12
Alentis Therapeutics–Piper Heartland Healthcare Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor PHHC	2024-11-12
Alentis Therapeutics–RA Capital: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor RA Capital Management	2024-11-12
Alentis Therapeutics–SEVERAL: investment, 202411 financing round Series D $181.4m led by OrbiMed with co-leads Novo Holdings + Jeito Capital	2024-11-12
Mainz Biomed–Thermo Fisher: colorectal cancer screening test, 202411– collab developm + commercialisation assays for mRNA-based CRC screening tests	2024-11-12
Mediaire–Berlin (govt): investment, 202411 financing round totalling €12m incl co-investor IBB Ventures	2024-11-12
Mediaire–G8Way Ventures: investment, 202411 financing round totalling €12m incl existing + co-investor Gateway Ventures	2024-11-12
Mediaire–High-Tech Gründerfonds: investment, 202411 financing round totalling €12m incl existing + co-investor HTGF	2024-11-12
Mediaire–LBO France: investment, 202411 financing round totalling €12m incl lead investor LBO France	2024-11-12
Mediaire–LIFTT (IT): investment, 202411 financing round totalling €12m incl existing + co-investor LIFTT	2024-11-12
Mediaire–SEVERAL: investment, 202411 financing round €12m led by LBO France	2024-11-12
Mediaire–Wille Finance: investment, 202411 financing round totalling €12m incl co-investor Wille Finance	2024-11-12
Zymofix–High-Tech Gründerfonds: investment, 202411 financing round totalling €2m incl lead investor HTGF	2024-11-12
Zymofix–SEVERAL: investment, 202411 financing round €2m led by HTGF	2024-11-12
Complihealth–Bertelsmann: investment, <=202411 investment by new investor Bertelsmann Investments in Guardoc Health	2024-11-07

1 2 3 ... 40 41 42

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)